Basta attivare l informativa che costa 3euro al mese ed é tutto in real time
bmsn
- Creatore Discussione axelvento
- Data di inizio
-
INVESTIMENTO IN LENDING CROWDFUNDING SU WALLIANCE: 21 MESI E CEDOLE TRIMESTRALI
Su Walliance è aperto l’investimento in Lending “Padova, Residence Linea 4.0”. Durata 21 mesi; distribuzione del TAN in cedole trimestrali; restituzione del capitale alla scadenza del finanziamento.
Campagna di raccolta investimenti > 90%.
Ticket minimo € 500.
Per continuare a leggere visita questo LINK
Basta attivare l informativa che costa 3euro al mese ed é tutto in real time
playars
lotto players
- Registrato
- 11/4/08
- Messaggi
- 8.306
- Punti reazioni
- 174
ho seguito il titolo in questi giorni
c'è da dire
sono entrati tanti dollari$$$$
volume sempre intenso!
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
abbiamo portato questo titolo dal otcbb al nasdaq http://www.finanzaonline.com/forum/otcbb-pinksheet/734163-plrs.html
stem cell
bmsn è il secondo??????????????????
tutto è possibile
stem cell
bmsn è il secondo??????????????????
tutto è possibile
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
Leggevo qua e là che il revisore dei conti non ha potuto esprimersi sul bilancio...siete sicuri(lo chiedo a voi che conoscete meglio di me le dinamiche della società)che non sia a rischio la continuità aziendale?Chiedo queste cose perché il grafico é molto bello e il titolo pur avendo guadagnato tanto dai minimi capitalizza una coppa grazie a chi mi rispondera
playars
lotto players
- Registrato
- 11/4/08
- Messaggi
- 8.306
- Punti reazioni
- 174
$BMSN and ent* has 4 trading days left or sooner before the MERGER!
ent* late filing ENTEST BIOMEDICAL, INC. (Form: NT 10-Q, Received: 01/14/2013 14:56:50)
$BMSN has been trading in this channel for a long time and being held here by ETRF.
Won't be long now before $BMSN will take off!
ent* late filing ENTEST BIOMEDICAL, INC. (Form: NT 10-Q, Received: 01/14/2013 14:56:50)
$BMSN has been trading in this channel for a long time and being held here by ETRF.
Won't be long now before $BMSN will take off!
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
news un ora prima della campana!
Regen BioPharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate(TM) Bone Marrow Failure Product
Regen BioPharma, a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today publication in a peer reviewed medical journal the scientific basis for its HemaXellerate™ bone marrow failure product. The manuscript is available at http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf. The publication is an overview of the Investigational New Drug (IND) application that the company plans to file for initiating clinical trials.
HemaXellerate™ is a cell therapy product developed by Regen BioPharma that uses fat derived from the patient as a source of "healing cells" to stimulate bone marrow production of blood cells. These "healing cells" are termed "endothelial cells" and are a critical component of the blood production machinery of the bone marrow that is damaged in patients with bone marrow failure.
Intellectual property covering the HemaXellerate™ product include US Provisional Patent applications 61/648898 - Acceleration of Hematopoietic Reconstitution by Placental Endothelial and Endothelial Progenitor Cells and 61/670791 - Treatment of Hematopoietic Disorders filed by Regen, as well as an option to exclusively license issued US Patent #6,821,513.
Currently, the only way to stimulate production of blood from bone marrow is through administration of growth factors. The overall market for growth factors is $18 billion per year. Unfortunately, growth factors require repeated administration, are expensive, and in many patients are ineffective.
"Treatments available today for patients with insufficient bone marrow function are a 'band-aid' solution that require repeated administration and do not address the underlying cause of bone marrow failure," said David Koos, Chairman and CEO of Bio-Matrix, and a co-author of the publication. "We believe that HemaXellerate™ offers the possibility to actually heal damage that has occurred to the bone marrow and thus more naturally treat the core of cause of bone marrow inactivity."
The publication contained data obtained from independent laboratories supporting the use of HemaXellerate™ as an alternative to growth factor therapy and was a co-authored by stem cell pioneers Dr. Amit Patel from University of Utah, and Dr. Michael Murphy from Indiana University. Additionally, the paper was co-authored by companies working in the field of stem cells including Cook Biotechnology and Medistem, Inc.
Regen BioPharma's first indication of HemaXellerate™ will be patients with aplastic anemia who are drug resistant and not eligible for bone marrow transplantation. Demonstration of efficacy in this patient population is anticipated to lead the way for entry into the $18 billion hematopoietic growth factor market which includes conditions such as anemia, thrombocytopenia, and chemotherapy associated leukopenia.
About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:
Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN) is a biotechnology company developing regenerative medicine therapies. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications.
Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. To follow our development, visit us at Regen BioPharma, Inc..
Bio-Matrix Scientific Group, Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
Regen BioPharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate(TM) Bone Marrow Failure Product
Regen BioPharma, a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today publication in a peer reviewed medical journal the scientific basis for its HemaXellerate™ bone marrow failure product. The manuscript is available at http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf. The publication is an overview of the Investigational New Drug (IND) application that the company plans to file for initiating clinical trials.
HemaXellerate™ is a cell therapy product developed by Regen BioPharma that uses fat derived from the patient as a source of "healing cells" to stimulate bone marrow production of blood cells. These "healing cells" are termed "endothelial cells" and are a critical component of the blood production machinery of the bone marrow that is damaged in patients with bone marrow failure.
Intellectual property covering the HemaXellerate™ product include US Provisional Patent applications 61/648898 - Acceleration of Hematopoietic Reconstitution by Placental Endothelial and Endothelial Progenitor Cells and 61/670791 - Treatment of Hematopoietic Disorders filed by Regen, as well as an option to exclusively license issued US Patent #6,821,513.
Currently, the only way to stimulate production of blood from bone marrow is through administration of growth factors. The overall market for growth factors is $18 billion per year. Unfortunately, growth factors require repeated administration, are expensive, and in many patients are ineffective.
"Treatments available today for patients with insufficient bone marrow function are a 'band-aid' solution that require repeated administration and do not address the underlying cause of bone marrow failure," said David Koos, Chairman and CEO of Bio-Matrix, and a co-author of the publication. "We believe that HemaXellerate™ offers the possibility to actually heal damage that has occurred to the bone marrow and thus more naturally treat the core of cause of bone marrow inactivity."
The publication contained data obtained from independent laboratories supporting the use of HemaXellerate™ as an alternative to growth factor therapy and was a co-authored by stem cell pioneers Dr. Amit Patel from University of Utah, and Dr. Michael Murphy from Indiana University. Additionally, the paper was co-authored by companies working in the field of stem cells including Cook Biotechnology and Medistem, Inc.
Regen BioPharma's first indication of HemaXellerate™ will be patients with aplastic anemia who are drug resistant and not eligible for bone marrow transplantation. Demonstration of efficacy in this patient population is anticipated to lead the way for entry into the $18 billion hematopoietic growth factor market which includes conditions such as anemia, thrombocytopenia, and chemotherapy associated leukopenia.
About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:
Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN) is a biotechnology company developing regenerative medicine therapies. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications.
Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. To follow our development, visit us at Regen BioPharma, Inc..
Bio-Matrix Scientific Group, Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
qualcosa di vero c'è scritto
prendere sempre con distacco....
Weekend DD Summary for $BMSN (read inside):
#1 On Friday January 25th, 2013 $BMSN was announced to be on NASDAQ's regulatory SHO list as an officially shorted stock where significant short positions had failed to deliver shares for an overextended period of time Regulation SHO Threshold Security List This tells us a massive amount of shares have been shorted and if those shares are not covered within the next couple days there will be SEVERE and IMMEDIATE financial obligations which the brokerage houses holding those accounts will be forced to pay. Have you ever heard of a brokerage house paying your bills on a bad trade--nope. Therefore these shares MUST be covered within the next couple days which will cause a significant surge in share price.
#2 On Saturday January 26th, 2013 http://otcshortreport.com , a very popular short report website listed $BMSN as being shorted by over 1 BILLION SHARES.. yes 1,000,000,000 since January 1st http://otcshortreport.com/bmsn
#3 Just yesterday, on Sunday January 27th, 2013 news had spread to ihub that BTNSR, a subsidiary run off of Sierra World Equity Review announced a Price Target of $1.55 for $BMSN's IND by the summer time just a day before Biotech News Stock Review: Bio-Matrix Scientific Group (BMSN) Price Target $1.55 By Summer_Investigational New Drug Application (IND) For HemaXellerate Turning Big Pharma Heads Forecasts Biotech News Stock Review
--------------------------------------------
Saturday, January 26, 2013
Bio-Matrix Scientific Group (BMSN) Price Target $1.55 By Summer_Investigational New Drug Application (IND) For HemaXellerate Turning Big Pharma Heads Forecasts Biotech News Stock Review
Bio-Matrix Scientific Group (BMSN) Price Target $1.55 By Summer_Investigational New Drug Application (IND) For HemaXellerate Turning Big Pharma Heads Forecasts Biotech News Stock Review.
Adam feels that BMSN could quite possible become the stock of the year. Look for an epic run to begin after the filing of the IND and not stop until summer when the share price will hit $1.55. Lots of people are going to get rich off the back of BMSN.
About Biotech News Stock Review
Adam and Johnny both love investing in biotech stocks, especially small companies that have promising drug pipelines. Adam is an avid researcher and very meticulous in his stock selections, Adam previously worked for Sierra World Equity Review where he was fundamental in helping select numerous accurate FDA calls. Adam has a law degree from Yale and is also fluent in Mandarin which he studied at the University of Beijing.
Johnny is a executive for a large pharmaceutical company based in New Jersey, with years of experience in his position as Managing Director for mergers and acquisitions with with special focus on China, Johnny brings valuable insight and perspective to the blogs daily stock posts.
If you enjoy buying and selling stocks, occasionally trade stocks online and enjoy the thrill of seeing your stock breakout after positive FDA trial results, then perhaps you may enjoy our blog! To maintain impartiality we never hold positions in any of the stocks we blog about.
Posted by Sierra World Equity Review at 10:44 PM
--------------------------------------------
In conclusion with a pending short squeeze, IND, and news/financials to be released by end of this week we are looking at a MASSIVE increase in share price to take place. This will last into the next 3-4 months with many ups and downs but a consistent uptrend at least to $0.50 A measly $2,000 investment at .003 will become $333,333 at .50
--------------------------------------------
OS SHARES LAST FILED
AS OF OCT 23,2012
OUTSTANDING 323M
REGEN BIOPHARMA, INC.
A Bio-Matrix wholly owned subsidiary,
Regen BioPharma has assessed over 20,000 stem cell related issued patents, narrowed down to 2000 patents with commercial applicability, and further identified 30 patents available for licensing. The company seeks to inlicense, take the product to, and through clinical safety and efficacy "signal" and spin out technologies.
WHY STEM CELL TRANPLANTS ARE UNSUCCESSFUL...STEM CELLS DIE AFTER A WEEK.
Method for enhancing hematopoiesis
Patent #6,821,513
prendere sempre con distacco....
Weekend DD Summary for $BMSN (read inside):
#1 On Friday January 25th, 2013 $BMSN was announced to be on NASDAQ's regulatory SHO list as an officially shorted stock where significant short positions had failed to deliver shares for an overextended period of time Regulation SHO Threshold Security List This tells us a massive amount of shares have been shorted and if those shares are not covered within the next couple days there will be SEVERE and IMMEDIATE financial obligations which the brokerage houses holding those accounts will be forced to pay. Have you ever heard of a brokerage house paying your bills on a bad trade--nope. Therefore these shares MUST be covered within the next couple days which will cause a significant surge in share price.
#2 On Saturday January 26th, 2013 http://otcshortreport.com , a very popular short report website listed $BMSN as being shorted by over 1 BILLION SHARES.. yes 1,000,000,000 since January 1st http://otcshortreport.com/bmsn
#3 Just yesterday, on Sunday January 27th, 2013 news had spread to ihub that BTNSR, a subsidiary run off of Sierra World Equity Review announced a Price Target of $1.55 for $BMSN's IND by the summer time just a day before Biotech News Stock Review: Bio-Matrix Scientific Group (BMSN) Price Target $1.55 By Summer_Investigational New Drug Application (IND) For HemaXellerate Turning Big Pharma Heads Forecasts Biotech News Stock Review
--------------------------------------------
Saturday, January 26, 2013
Bio-Matrix Scientific Group (BMSN) Price Target $1.55 By Summer_Investigational New Drug Application (IND) For HemaXellerate Turning Big Pharma Heads Forecasts Biotech News Stock Review
Bio-Matrix Scientific Group (BMSN) Price Target $1.55 By Summer_Investigational New Drug Application (IND) For HemaXellerate Turning Big Pharma Heads Forecasts Biotech News Stock Review.
Adam feels that BMSN could quite possible become the stock of the year. Look for an epic run to begin after the filing of the IND and not stop until summer when the share price will hit $1.55. Lots of people are going to get rich off the back of BMSN.
About Biotech News Stock Review
Adam and Johnny both love investing in biotech stocks, especially small companies that have promising drug pipelines. Adam is an avid researcher and very meticulous in his stock selections, Adam previously worked for Sierra World Equity Review where he was fundamental in helping select numerous accurate FDA calls. Adam has a law degree from Yale and is also fluent in Mandarin which he studied at the University of Beijing.
Johnny is a executive for a large pharmaceutical company based in New Jersey, with years of experience in his position as Managing Director for mergers and acquisitions with with special focus on China, Johnny brings valuable insight and perspective to the blogs daily stock posts.
If you enjoy buying and selling stocks, occasionally trade stocks online and enjoy the thrill of seeing your stock breakout after positive FDA trial results, then perhaps you may enjoy our blog! To maintain impartiality we never hold positions in any of the stocks we blog about.
Posted by Sierra World Equity Review at 10:44 PM
--------------------------------------------
In conclusion with a pending short squeeze, IND, and news/financials to be released by end of this week we are looking at a MASSIVE increase in share price to take place. This will last into the next 3-4 months with many ups and downs but a consistent uptrend at least to $0.50 A measly $2,000 investment at .003 will become $333,333 at .50
--------------------------------------------
OS SHARES LAST FILED
AS OF OCT 23,2012
OUTSTANDING 323M
REGEN BIOPHARMA, INC.
A Bio-Matrix wholly owned subsidiary,
Regen BioPharma has assessed over 20,000 stem cell related issued patents, narrowed down to 2000 patents with commercial applicability, and further identified 30 patents available for licensing. The company seeks to inlicense, take the product to, and through clinical safety and efficacy "signal" and spin out technologies.
WHY STEM CELL TRANPLANTS ARE UNSUCCESSFUL...STEM CELLS DIE AFTER A WEEK.
Method for enhancing hematopoiesis
Patent #6,821,513
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
